| Hadia Crider, MD | |
|
1000 W Nifong Blvd, Columbia, MO 65203-5615 | |
| (888) 403-1071 | |
| Not Available |
| Full Name | Hadia Crider |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1000 W Nifong Blvd, Columbia, Missouri |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487094140 | NPI | - | NPPES |
| Entity Name | Phelps County Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891766051 PECOS PAC ID: 2860391158 Enrollment ID: O20040106000405 |
News Archive
Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.
Examining more than 20 years of national data for U.S. adolescents, a research team led by Andrew Subica at the University of California, Riverside reports that adolescents have high prevalence of alcohol, cigarette, and marijuana use, and concerning rates of suicide-related thoughts and behaviors.
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.
› Verified 9 days ago
| Entity Name | Compass Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285619494 PECOS PAC ID: 1951206754 Enrollment ID: O20040408000955 |
News Archive
Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.
Examining more than 20 years of national data for U.S. adolescents, a research team led by Andrew Subica at the University of California, Riverside reports that adolescents have high prevalence of alcohol, cigarette, and marijuana use, and concerning rates of suicide-related thoughts and behaviors.
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.
› Verified 9 days ago
| Entity Name | Pcrmc Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124237227 PECOS PAC ID: 1557454063 Enrollment ID: O20070829000437 |
News Archive
Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.
Examining more than 20 years of national data for U.S. adolescents, a research team led by Andrew Subica at the University of California, Riverside reports that adolescents have high prevalence of alcohol, cigarette, and marijuana use, and concerning rates of suicide-related thoughts and behaviors.
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hadia Crider, MD 1800 Community, Clinton, MO 64735-8804 Ph: (660) 885-8131 | Hadia Crider, MD 1000 W Nifong Blvd, Columbia, MO 65203-5615 Ph: (888) 403-1071 |
News Archive
Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.
Laboratories at The Scripps Research Institute (TSRI) are investigating antibodies to fight Ebola virus, including the three antibodies recently used to treat two American health care workers infected with the Ebola virus.
Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold.
Examining more than 20 years of national data for U.S. adolescents, a research team led by Andrew Subica at the University of California, Riverside reports that adolescents have high prevalence of alcohol, cigarette, and marijuana use, and concerning rates of suicide-related thoughts and behaviors.
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for the treatment of Pompe disease. An investigational new drug application (IND) for BMN-701 has been submitted, investigational material has been manufactured and a Phase I/II study is expected to start in the first quarter of 2011.
› Verified 9 days ago
Dr. Anasseril E Daniel, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 33 E Broadway Ste 115, Columbia, MO 65203 Phone: 573-443-6930 Fax: 573-875-4272 | |
Dr. Joseph J. Parks, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: Family Health Center Of Boone County, 1001 West Worley, Columbia, MO 35203 Phone: 573-214-2314 Fax: 573-814-2784 | |
Dr. Robert Edward Frazier, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 367 Crown Pt, Columbia, MO 65203 Phone: 573-442-4346 Fax: 573-443-2027 | |
Myles Brandon Goble, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 525 N. Keene Street, Suite 301, Columbia, MO 65201 Phone: 573-882-2260 Fax: 573-884-4249 | |
Ashutosh Pandey, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1020 Hitt St, Columbia, MO 65212 Phone: 573-882-1515 | |
Jeffrey Thiele, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6000 | |
Lisa A Lacey, D.O. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 800 Hospital Dr, Columbia, MO 65201 Phone: 573-814-6480 |